Journal
DRUG DISCOVERY TODAY
Volume 15, Issue 9-10, Pages 332-341Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2010.02.003
Keywords
-
Categories
Funding
- NIH [HL82779, HL83966, HL090920]
- NSFC [30973211]
- Jiangsu/Suzhou Grants [90134602, SZS0602]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083966, R01HL089012, R01HL082779, R01HL090920] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Angiotensin-converting enzyme (ACE) is a major target in the treatment of cardiovascular diseases (CVDs). In addition to ACE, ACE2 - which is a homolog of ACE and promotes the degradation of angiotensin II (Ang II) to Ang (1-7) - has been recognized recently as a potential therapeutic target in the management of CVDs. This article reviews different metabolic pathways of ACE and ACE2 (Ang I-Ang II-AT1 receptors and Ang I-Ang (1-7)-Mas receptors) in the regulation of cardiovascular function and their potential in new drug development in the therapy of CVDs. In addition, recent progress in the study of angiotensin and ACE in fetal origins of CVD, which might present an interesting field in perinatal medicine and preventive medicine, is briefly summarized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available